5-(3-Chlorophenyl)-1,2-oxazol-4-amine | 1404050-69-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(3-Chlorophenyl)-1,2-oxazol-4-amine
• 英文别名: 5-(3-chlorophenyl)-1,2-oxazol-4-amine
• CAS: 1404050-69-6
• 化学式: C₉H₇ClN₂O
• 分子量: 194.62
• InChiKey: ICZCUIRXAOGVSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-chloropyrazolo[1,5-a]pyrimidine-3-carbonyl chloride 、 5-(3-Chlorophenyl)-1,2-oxazol-4-amine 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以65%的产率得到5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylic acid [5-(3-chlorophenyl)isoxazol-4-yl]amide
  参考文献：
  名称：

  Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors

  摘要：

  The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in disc-ova-ring selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibit-or of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of 7j. In a SET2 xenograft model that is dependent on Jak2 for growth, 7j demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.

  DOI：

  10.1021/jm3012239

文献信息

• PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
  申请人：Genentech, Inc.

  公开号：US20140107099A1

  公开（公告）日：2014-04-17

  The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

  本发明提供了JAK激酶抑制剂Ia的公式，其对映体、对映异构体或其药学上可接受的盐，其中R1，R2，R7和Z在此定义，以及包括公式Ia化合物和药学上可接受的载体、佐剂或载体的制药组合物，以及用于治疗或减轻患者对JAK激酶活性抑制敏感的疾病或病情严重程度的方法。
• US8637526B2
  申请人：——

  公开号：US8637526B2

  公开（公告）日：2014-01-28
• Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors
  作者：Emily J. Hanan、Anne van Abbema、Kathy Barrett、Wade S. Blair、Jeff Blaney、Christine Chang、Charles Eigenbrot、Sean Flynn、Paul Gibbons、Christopher A. Hurley、Jane R. Kenny、Janusz Kulagowski、Leslie Lee、Steven R. Magnuson、Claire Morris、Jeremy Murray、Richard M. Pastor、Tom Rawson、Michael Siu、Mark Ultsch、Aihe Zhou、Deepak Sampath、Joseph P. Lyssikatos

  DOI：10.1021/jm3012239

  日期：2012.11.26

  The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in disc-ova-ring selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibit-or of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of 7j. In a SET2 xenograft model that is dependent on Jak2 for growth, 7j demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.